AID Cann News
15 articles
יוניבו תספק קנאביס רפואי למטופלי הכללית בחוזה של "מיליוני שקלים בשנה" כלכליסט
יוניבו, a medical cannabis company, has been selected as a provider of medical cannabis products for the General Health Insurance Fund. This partnership allows patients insured by the fund to purchase Yonivos products at a discounted price. With approximately 100,000 medical cannabis patients in Israel, Yonivo has the potential for significant revenue growth. The company reported a 90% increase in revenue in the first half of 2021 compared to the previous year. Yonivo also recently won a tender to supply medical cannabis oils to Israeli prisons. The company aims to increase its market share in Israel to 15% in the near future. Yonivo is a leading player in the Israeli medical cannabis industry, with full control over the supply chain.
Customers
צעצוע של עשירים: ניר צוק משקיע בחברת הקנאביס יוניבו
ניר צוק, מייסד חברת אבטחת הסייבר פאלו אלטו, ישקיע 11.1 מיליון שקל בחברת הקנאביס יוניבו. ההודעה גרמה לקפיצת מניית יוניבו בבורסה התל אביבית בערך 24%. ניר צוק יקבל 5% מהון החברה במחיר אפקטיבי של 4.62 שקלים למניה, פרמיה של 84% על מחיר השוק של המניות. כמו כן, יקבל אופציות לעוד כ-5% מהחברה במקרה שמחיר המניה יעמוד על יותר מ-7.1 שקלים למניה. יוניבו היא חברת קנאביס הרפואי המתמחה בעיבוד, יבוא ושיווק של מוצרים קנאביס רפואיים.
Investment
https://www.jpost.com/health-science/israeli-medical-cannabis-firm-univo-acquires-pharmacy-medipharm-671013
Univo, an Israeli medical cannabis product firm, has acquired control of the pharmacy Medipharm for $1.7 million. This acquisition is part of Univos strategy to have complete control over the production chain of medical cannabis. Univo distributes its products in over 140 pharmacies, including Super-Pharm and BE chains. The acquisition of Medipharm is expected to lead to revenue and profit growth, as well as an increase in market share. Univo plans to explore additional collaborations in Israel and abroad to create more value for its shareholders.
CustomersPartners
Fluence Expands Footprint in Burgeoning Israeli Cannabis Industry, Supports Multiple Cultivators Through REMY Partnership
Fluence by OSRAM, a global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, has announced its implementations with two major cannabis cultivators in Israel, Springs Valley Cannabis LTD and UNIVO Pharmaceuticals, through its ongoing partnership with REMY LTD, a leading horticultural lighting provider in Israel. This comes as Israels cannabis industry continues to grow, with nearly 30 cultivators actively producing medical cannabis and dozens more in planning stages. Fluences LED lighting solutions and research-backed cultivation methods are being used to achieve high-quality, consistent crops while conserving heating, ventilation and air conditioning costs.
PartnersExpand
DNA Genetics Announces Strategic Alliance Agreement With Vertically-Integrated Israeli Cannabis Company, UNIVO Pharmaceuticals
OG DNA Genetics has announced a licensing agreement with UNIVO Pharmaceuticals, granting UNIVO access to DNAs proprietary library of genetics for use in their cultivation facility in Israel. The partnership aims to develop cannabis-derived medicinal products for export. DNA Genetics is a globally recognized cannabis brand with numerous awards for their genetics. UNIVO Pharmaceuticals is an Israeli medical cannabis company. The agreement is seen as a growth-positive move for DNA Genetics.
Partners
Israeli Cannabis Co. Univo Will Enter The U.K. Market - Benzinga
Univo Pharmaceuticals has entered into a distribution deal in the UK, where up to five tons of its cannabis-based products will be distributed annually. The agreement has a duration of three years and will be automatically renewed. Univo aims to expand into the international market and has experienced strong growth in its domestic activity. Earlier, the company entered a pilot program in Israel to reduce product prices and obtain expedited export permits. Univo has also applied for an export permit to Brazil.
Partners
Univo importing cannabis to Israel from Lesotho, Canada
Univo, an Israeli cannabis manufacturer, has received approval to import cannabis from Canada and Lesotho. They have imported a small amount of cannabis from Canopy Growth in Lesotho and plan to import 500 kilograms. Univo has also received approval to import Minerva inflorescences from Canada. They are the first medical cannabis company to engage in commercial operations in the Israeli market. Univo has a processing factory in Israel and is already selling medical cannabis products under its own brand. They have also formed a partnership with Kineret pharmacy for distribution. Univo has sales agreements for up to 20 tons of medical cannabis.
PartnersCustomers
Univo teams with Canada's Canopy on medical cannabis
Israeli medical cannabis company Univo has signed a cooperation agreement with Canopy Growth, a leading cannabis company. Univo will import 470 kilograms of cannabis from Canopy Growth and become their exclusive importer in Israel. In the future, Canopy Growth will also be able to use Univos processing and distribution services for Europe. This agreement allows Univo to increase its market share in Israel and establish production infrastructure for Canopy Growth in the international market. This is the second agreement between an Israeli cannabis company and an international firm. The agreement highlights the continued interest of Canadian companies in the Israeli market.
PartnersCustomers
Can-Fite and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects
Cannabis co Univo raises NIS 12m from Avisror Group
Avisror Group is investing NIS 12 million in medical cannabis company Univo and its Amit Farm. The investment includes buying 1.2 million shares of Univo for NIS 6 million and loaning NIS 6 million to Amit Farm in exchange for a 23% stake. Univo will hold 51% of Amit Farm after the completion of the allotment. Univo has received approvals for full commercial operations and is working to expedite the construction of Amit Farm.
Investment
Univo medical cannabis approved for pharmacy sales
Univo has received IMC-GMP and IMC-GDP approval for its medical cannabis manufacturing plant, allowing the company to commence sales of its products in Israeli pharmacies. Univo anticipates generating revenue before the end of 2019 and is positioned at the forefront of Israels emerging cannabis industry. The company owns a medical cannabis farm and aims to have full control over the value chain, from cultivation to marketing. Univo is also preparing to meet EU standards to export cannabis to overseas markets. The company completed construction of its facility in Ashkelon in April 2019 and holds all licenses across the value chain in Israel.
CustomersPartners
Hagag, Hurvitz investing NIS 3m more in Univo
Businessperson Ido Hagag, along with other investors including Chaim Hurvitz, is increasing his investment in Univo Pharmaceuticals by investing an additional NIS 3 million. However, the cannabis sector on the Tel Aviv Stock Exchange has seen plummeting share prices, with Univos share price dropping 50% since April. The Israeli governments approval of medical cannabis exports has not yet resulted in any actual exports, as there are still hurdles to overcome, including the development of export standards, differences between Israeli and European standards, and the signing of a trade agreement between Israel and the European Union.
Investment
Ehud Olmert joins Israeli cannabis co Univo
Former Israeli Prime Minister Ehud Olmert has invested in Univo Pharmaceuticals and will act as an advisor. Univo has received licenses for the cultivation, R&D, production, and distribution of cannabis products. Olmert will earn a salary of $10,000 per month plus share options. Univo is developing a new facility for research and development. Olmerts involvement is seen as a positive growth opportunity for the company.
Investment
UNV signs new deal with Israeli cannabis startup
UNV-Medicine, a company in the cannabis growing sector, has announced a deal to manufacture a cannabis product for a startup in its facility. The startup will buy the active ingredient for its products from UNV. The initial payments for the deal were not disclosed. UNV will receive a steady stream of revenue from planning the activity, even before the facility is launched. D-Pharm, which recently merged with UNV-Medicine, saw a 2.43% increase in its share price on the news.
PartnersAcquisition
Chinese regulator approves D-Pharm epilepsy drug trial
D-Pharm has received approval from the Chinese Food and Drug Administration (C-FDA) for clinical development of epilepsy treatment DP-VPA. D-Pharm is collaborating with Jiangsu Nhwa Pharmaceutical Co., Ltd. on the development of DP-VPA. Nhwa will begin with a bridging safety study, followed by a large dose-ranging Phase IIb clinical study in epilepsy patients. DP-VPA is a derivative of valproic acid and has shown safety and efficacy in previous clinical studies. D-Pharm has the rights for DP-VPA in the rest of the world, while Nhwa has responsibility for development, manufacturing, registration, and marketing in China, Hong Kong, and Macau.
Partners
